Boston-Area Biotech Firms Get Research Grants
Posted on: Thursday, 17 March 2005, 21:00 CST
Mar. 18--The Cystic Fibrosis Foundation gave research grants to two Boston-area biotechnology companies this week to help advance a treatment for the rare genetic disease.
The foundation gave grants that could reach $12.5 million to Predix Pharmaceuticals Holdings Inc. of Woburn, a private drug company with several drug candidates in early-stage clinical trials. Predix will use its three-dimensional modeling technology to explore a defective protein that influences transport of salt and water across cell membranes in those afflicted with cystic fibrosis.
The company will also use its modeling technology to develop a drug that can act against the defective protein. Such a drug could ease the symptoms of those with cystic fibrosis. The company will retain the right to develop and commercialize any drugs that result from the second program.
Separately, the foundation awarded a grant worth up to $1.5 million to Alnylam Pharmaceuticals Inc. of Cambridge to develop therapeutics to treat the disease. Alnylam is a leader in so-called RNA interference technology, in which drugs are used to block the instructions from disease-causing genes.
A genetic mutation leaves cystic fibrosis patients with a defective protein that makes it difficult for cells to regulate their levels of salt and water. That leads to numerous symptoms including thick, sticky mucus in the lungs and pancreas; difficulty digesting food; and serious lung infections.
About 30,000 people have the disease in the United States, and half of those patients die before reaching their mid-30s, according to the foundation.
-----
To see more of The Boston Globe, or to subscribe to the newspaper, go to http://www.boston.com/globe.
Copyright (c) 2005, The Boston Globe
Distributed by Knight Ridder/Tribune Business News.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
Source: The Boston Globe
Related Articles
- Drug promising as cystic fibrosis therapy
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
- GNI Receives Approval for Liver Disease Drug
- Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort
- Register Now for the 8th International Conference on Alzheimer's Disease Drug Discovery
- Researchers Designing Better Drug to Treat Cystic Fibrosis
- Anti-inflammatory Function of Alzheimer's Disease Drugs Revealed
- Chairman of CytRx Metabolic SAB and President of CytRx Laboratories Address 4th International Metabolic Diseases Drug Discovery World Summit
- Crohn's Disease Drug Market to Experience Dynamic Growth of 73% By 2013
 |
 |
User Comments (0)
RSS Feeds